Ally Financial Inc. Buys New Shares in IQVIA Holdings Inc. $IQV

Ally Financial Inc. purchased a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 5,500 shares of the medical research company's stock, valued at approximately $1,063,000.

A number of other hedge funds have also recently bought and sold shares of IQV. Cibc World Market Inc. acquired a new position in shares of IQVIA during the 2nd quarter worth approximately $11,294,000. Castlefield Investment Partners LLP acquired a new position in IQVIA during the second quarter worth $601,000. OMERS ADMINISTRATION Corp bought a new stake in IQVIA during the second quarter worth $1,812,000. Osmosis Investment Management UK Ltd bought a new position in shares of IQVIA in the 2nd quarter valued at about $895,000. Finally, Sanctuary Advisors LLC bought a new position in shares of IQVIA in the 2nd quarter valued at about $1,643,000. 89.62% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on IQV. Mizuho upped their target price on shares of IQVIA from $215.00 to $230.00 and gave the company an "outperform" rating in a report on Monday, July 13th. Weiss Ratings upgraded IQVIA from a "hold (c-)" rating to a "hold (c)" rating in a report on Wednesday, July 15th. Royal Bank Of Canada upped their price objective on IQVIA from $221.00 to $247.00 and gave the company an "outperform" rating in a research note on Wednesday, July 29th. William Blair raised IQVIA to a "strong-buy" rating in a research report on Tuesday, July 28th. Finally, Wall Street Zen upgraded IQVIA from a "hold" rating to a "buy" rating in a research note on Saturday, August 1st. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $241.88.

Insider Buying and Selling at IQVIA

In related news, insider W Richard Staub sold 5,500 shares of the business's stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $232.68, for a total value of $1,279,740.00. Following the completion of the sale, the insider directly owned 13,312 shares in the company, valued at approximately $3,097,436.16. The trade was a 29.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Bhavik Patel sold 1,855 shares of the firm's stock in a transaction on Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the transaction, the insider owned 1,348 shares in the company, valued at approximately $317,143.96. This trade represents a 57.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 12,913 shares of company stock worth $3,098,793. 1.70% of the stock is currently owned by company insiders.

IQVIA Stock Up 0.1%

IQV stock opened at $260.17 on Monday. IQVIA Holdings Inc. has a fifty-two week low of $154.50 and a fifty-two week high of $260.40. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. The stock has a market capitalization of $42.82 billion, a price-to-earnings ratio of 32.28, a PEG ratio of 2.21 and a beta of 1.18. The business's fifty day moving average price is $213.32 and its two-hundred day moving average price is $187.21.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating the consensus estimate of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business had revenue of $4.37 billion for the quarter, compared to the consensus estimate of $4.30 billion. During the same period in the prior year, the company posted $2.81 earnings per share. IQVIA's revenue was up 8.7% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. On average, equities analysts anticipate that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA declared that its Board of Directors has approved a share buyback program on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to buy up to 6.8% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's board believes its shares are undervalued.

IQVIA Company Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source